11 May 2022

4basebio plc
(the "Company")
 

Director’s Dealing

4basebio PLC (AIM: 4BB), the specialist life sciences group focused on exploiting intellectual property in the field of cell and gene therapies and DNA vaccines, announces that, on 09 May 2022, Heikki Lanckriet, chief executive officer, acquired 500 ordinary shares at a price of 500 pence per share.

As a result of the acquisition of ordinary shares, Heikki Lanckriet’s beneficial holding, including shares held by persons closely associated with him, comprises 1,249,453 ordinary shares representing 10.14 per cent. of the Company’s issued share capital.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

For further enquiries, please contact:

4basebio plc                +44 (0)12 2396 7943
Heikki Lanckriet, CEO
Cairn Financial Advisers LLP (Nominated Adviser) +44 (0)20 7213 0880
Jo Turner / Sandy Jamieson
finnCap Ltd (Broker) +44 (0)20 7220 0500
Geoff Nash/Richard Chambers/Charlotte Sutcliffe

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1.        Details of the person discharging managerial responsibilities/person closely associated

a.        Name                                                    Heikki Lanckriet

2.        Reason for notification

a.        Position/Status                                   Chief Executive Officer

b.        Initial notification/ Amendment    Initial

3.        Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.        Name                                                    4basebio plc

b.        LEI                                                          213800E2DX9EAIUNCB30

4.        Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.        Description of the financial instrument, type Ordinary Shares of instrument

Identification Code                            ISIN: GB00BMCLYF79
 

b.        Nature of the transaction                Acquisition of ordinary shares
 

c.         Price(s) and volume(s)       Volume(s)           Price (p)
 

500 500p

d.        Aggregated information  

- Aggregated Volume                        500
- Price                                                    500 pence per share
 

e.        Date of the transaction                    09/05/2022
 

f.         Place of the transaction London Stock Exchange, AIM